CN113755602A - Gene marker for identifying lung adenocarcinoma tumor stem cells and application thereof - Google Patents

Gene marker for identifying lung adenocarcinoma tumor stem cells and application thereof Download PDF

Info

Publication number
CN113755602A
CN113755602A CN202111218705.7A CN202111218705A CN113755602A CN 113755602 A CN113755602 A CN 113755602A CN 202111218705 A CN202111218705 A CN 202111218705A CN 113755602 A CN113755602 A CN 113755602A
Authority
CN
China
Prior art keywords
lung adenocarcinoma
stem cells
tumor stem
identifying
marker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111218705.7A
Other languages
Chinese (zh)
Inventor
陈振淙
詹成
梁嘉琪
胡正阳
尹嘉成
隋启海
林宗武
王群
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhongshan Hospital Fudan University
Original Assignee
Zhongshan Hospital Fudan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhongshan Hospital Fudan University filed Critical Zhongshan Hospital Fudan University
Priority to CN202111218705.7A priority Critical patent/CN113755602A/en
Publication of CN113755602A publication Critical patent/CN113755602A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6851Quantitative amplification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to a gene marker for identifying lung adenocarcinoma tumor stem cells and application thereof, belonging to the technical field of biological medicines. The gene marker is selected from the group consisting of genes RPS4X, FTH1, CYBA, POMP, SLC25A5, RPL35A, BST2, SEC61G, HMGB1, COMMD6, CLIC1, COX6B1, NDUFB4, TPI1, COX8A, SAP18, HMGN1 and XIST. The lung adenocarcinoma tumor stem cell marker obtained based on single-cell transcriptome sequencing can accurately identify lung adenocarcinoma stem cells in lung adenocarcinoma, is not limited to dry genes on the cell surface, and provides a new molecular target for further research on the lung adenocarcinoma stem cells and treatment aiming at the lung adenocarcinoma stem cells.

Description

Gene marker for identifying lung adenocarcinoma tumor stem cells and application thereof
Technical Field
The invention relates to a gene marker for identifying lung adenocarcinoma tumor stem cells and application thereof, belonging to the technical field of biological medicines.
Background
The incidence and mortality of lung cancer is ranked in the prostate among all tumors, with the most prominent lung cancer subtype being lung adenocarcinoma. At present, although clinical treatment means aiming at the lung adenocarcinoma are diversified, the overall survival rate of patients is still poor, so that it is necessary to further improve the effectiveness of the current treatment means for the lung adenocarcinoma. The lung adenocarcinoma tumor stem cells are a small group of cell types with self-renewal and differentiation potential in lung adenocarcinoma tissues, and play an important role in the proliferation, metastasis and chemoradiotherapy drug resistance of lung adenocarcinoma. Further and deeply researching the lung adenocarcinoma stem cells has important significance for overcoming the lung adenocarcinoma. However, in the past, researchers usually defined the dryness of cells by a flow method, i.e., by the dryness gene on the cell surface, which has fewer selectable marker genes on one hand and more complicated operations on the other hand. Therefore, it is necessary to develop a gene marker for identifying tumor stem cells in lung adenocarcinoma. Therefore, a convenient and accurate gene combination with higher sensitivity, specificity and application value can still exist, and the gene combination can be applied to distinguishing lung adenocarcinoma stem cells from common lung adenocarcinoma cells.
The advent of single cell transcriptome sequencing in recent years has enabled researchers to detect cell expression at the single cell level. Stem cells in lung adenocarcinoma can be studied at the level of single cells by single-cell transcriptome sequencing, thereby obtaining a specific expression profile (i.e. lung adenocarcinoma stem cell gene marker combination) for identifying lung adenocarcinoma stem cells. This will help researchers to more accurately distinguish tumor stem cells in lung adenocarcinoma.
Disclosure of Invention
The invention aims to solve the technical problems of obtaining a gene marker for identifying lung adenocarcinoma tumor stem cells and application thereof.
In order to solve the above problems, the present invention provides a genetic marker for identifying lung adenocarcinoma tumor stem cells, wherein the genetic marker comprises at least one of genes RPS4X, FTH1, CYBA, POMP, SLC25a5, RPL35A, BST2, SEC61G, HMGB1, COMMD6, CLIC1, COX6B1, NDUFB4, TPI1, COX8A, SAP18, HMGN1, and XIST.
The invention provides an application of a gene marker for identifying lung adenocarcinoma tumor stem cells in preparing a diagnostic kit for detecting the lung adenocarcinoma tumor stem cells.
The invention provides application of a gene marker for identifying lung adenocarcinoma tumor stem cells in preparation of a diagnostic kit for lung adenocarcinoma prognosis.
The invention provides application of a gene marker for identifying lung adenocarcinoma tumor stem cells in preparation of a medicament for treating lung adenocarcinoma.
The invention provides application of a gene marker for identifying lung adenocarcinoma tumor stem cells in a non-diagnosis method and a non-treatment method.
Compared with the prior art, the invention has the following beneficial effects:
1. the lung adenocarcinoma tumor stem cell marker obtained based on single-cell transcriptome sequencing can accurately identify lung adenocarcinoma stem cells in lung adenocarcinoma, is not limited to dry genes on the cell surface, and provides a new molecular target for further research on the lung adenocarcinoma stem cells and treatment aiming at the lung adenocarcinoma stem cells.
2. The risk assessment model can be established based on a machine learning method, and has the advantages of quantitative analysis, high accuracy and good sensitivity and specificity.
Drawings
FIG. 1 is a graph showing the clustering results of tumor stem cells and non-tumor stem cells of lung adenocarcinoma;
FIG. 2 is a ROC graph of 18 genes such as RPS4X in differentiating tumor stem cells and non-tumor stem cells of lung adenocarcinoma;
wherein the abscissa represents specificity and the ordinate represents sensitivity;
FIG. 3 is a ROC plot of a risk assessment model constructed based on 18 genes, such as RPS 4X;
wherein the abscissa represents specificity and the ordinate represents sensitivity;
FIG. 4 is a graph showing the results of RT-qPCR method to detect the difference of 18 gene mRNA expression such as RPS4X in tumor stem cells and non-tumor stem cells in lung adenocarcinoma;
where the ordinate represents the fold difference in mRNA expression.
Detailed Description
In order to make the invention more comprehensible, preferred embodiments are described in detail below with reference to the accompanying drawings:
the invention provides a gene marker for identifying lung adenocarcinoma tumor stem cells, which comprises at least one of genes RPS4X, FTH1, CYBA, POMP, SLC25A5, RPL35A, BST2, SEC61G, HMGB1, COMMD6, CLIC1, COX6B1, NDUFB4, TPI1, COX8A, SAP18, HMGN1 and XIST.
The invention provides an application of a gene marker for identifying lung adenocarcinoma tumor stem cells in preparing a diagnostic kit for detecting the lung adenocarcinoma tumor stem cells.
The invention provides application of a gene marker for identifying lung adenocarcinoma tumor stem cells in preparation of a diagnostic kit for lung adenocarcinoma prognosis.
The invention provides application of a gene marker for identifying lung adenocarcinoma tumor stem cells in preparation of a medicament for treating lung adenocarcinoma.
The invention provides application of a gene marker for identifying lung adenocarcinoma tumor stem cells in a non-diagnosis method and a non-treatment method.
Example 1
Screening of the gene set:
analyzing a single cell sequencing result of lung adenocarcinoma tissues;
tumor tissue samples of 10 lung adenocarcinoma samples were first obtained and dissociated to prepare single cell suspensions. The lung adenocarcinoma tumor stem cells were then initially sorted by flow sorting based on the currently recognized tumor stem cell marker genes (CD133 and ALDH1) and tumor marker gene (EPCAM). These sorted tumor stem cells were then subjected to single cell transcriptome sequencing with the remaining common tumor cells and off-line data was obtained. Based on this sequencing, a total of 46106 single cell gene expression data were obtained.
And (4) completing dimension reduction and cluster analysis of the single cell data by using a Seurat packet through an R language. Subsequently 6955 lung adenocarcinoma tumor stem cells were identified based on putative cell markers (fig. 1). After the cell identification was completed, the transcriptome differential analysis of tumor stem cells and common lung adenocarcinoma cells in lung adenocarcinoma was completed using the "FindMakrers" function (± 0.5 is log2FC cutoff), resulting in 230 genes up-regulated in tumor stem cells in lung adenocarcinoma and 152 genes down-regulated in tumor stem cells in lung adenocarcinoma.
After the screening of the differential genes is completed, the marker genes capable of better distinguishing the lung adenocarcinoma tumor stem cells from the non-tumor stem cells are screened by the pROC package in the R language, and 55 genes with the area under the ROC curve (AUC) value of more than 0.87 are included and enter the next Lasso regression analysis.
After the primary screening of the lung adenocarcinoma tumor stem cell marker genes is completed, the marker genes are further screened by a method of Lasso regression, and eighteen genes are obtained: RPS4X, FTH1, CYBA, POMP, SLC25A5, RPL35A, BST2, SEC61G, HMGB1, COMMD6, CLIC1, COX6B1, NDUFB4, TPI1, COX8A, SAP18, HMGN1, XIST. The AUC values, sensitivity and specificity values of the 18 genes are shown in table 1 and fig. 2:
TABLE 1 AUC, sensitivity and idiosyncratic values of genes for constructing a lung adenocarcinoma tumor stem cell risk assessment model
Gene AUC Sensitivity of the composition Specificity of
RPS4X 0.924269 0.862246 0.845866
FTH1 0.901666 0.838529 0.809346
CYBA 0.905836 0.821226 0.86197
POMP 0.918887 0.877163 0.833789
SLC25A5 0.899039 0.866423 0.790079
RPL35A 0.90888 0.833234 0.837958
BST2 0.874737 0.831817 0.81711
SEC61G 0.89172 0.810263 0.819986
HMGB1 0.92438 0.876492 0.824874
COMMD6 0.893396 0.849717 0.803019
CLIC1 0.87347 0.818243 0.788641
COX6B1 0.881678 0.849567 0.756147
NDUFB4 0.883504 0.830474 0.796262
TPI1 0.881813 0.878505 0.734292
COX8A 0.872772 0.780579 0.816966
SAP18 0.899207 0.857921 0.800719
HMGN1 0.894659 0.857249 0.775988
XIST 0.871428 0.783189 0.921783
A scoring model was constructed by Logistic regression:
Score=0.252*RPS4X+0.609*FTH1+0.287*CYBA+0.358*POMP+0.477*SLC25A5+0.586*RPL35A+0.197*BST2+0.444*SEC61G+0.420*HMGB1+0.351*COMMD6+0.626*CLIC1+0.512*COX6B1+0.426*NDUFB4+0.379*TPI1+0.850*COX8A+0.480*SAP18+0.498*HMGN1-1.373*XIST;
the Logistic regression risk model was then validated for its effect using the single cell transcriptome data in example 1. According to the model, the normalized expression value (unit: TPM) of the corresponding gene is substituted into a scoring model, and the result shows that the specificity and the sensitivity of the risk model are improved to a certain extent compared with a single-gene model, and the AUC value is close to 0.95, which shows that the prediction model can more accurately distinguish lung adenocarcinoma tumor stem cells and non-lung adenocarcinoma tumor stem cells (figure 3). The cutoff value for Score in this model was 8.5. According to the model, when the value obtained by the Score calculation formula is more than 8.5, the cell is judged as the lung adenocarcinoma tumor stem cell; when the value obtained by the Score calculation formula is less than 8.5, the cell is judged as a common lung adenocarcinoma cell.
Example 2 effect verification:
flow cytometry sorting lung adenocarcinoma tumor stem cells and non-tumor stem cells to verify gene expression:
the fold difference of mRNA expression of the 18 genes was detected in the selected lung adenocarcinoma tumor stem cells and common lung adenocarcinoma cells by RT-qPCR method, and the result is shown in FIG. 4. From the results in fig. 4, it is known that 18 genes of RPS4X, FTH1, CYBA, POMP, SLC25a5, RPL35A, BST2, SEC61G, HMGB1, COMMD6, CLIC1, COX6B1, NDUFB4, TPI1, COX8A, SAP18, HMGN1, and XIST are generally expressed in higher amounts in lung adenocarcinoma tumor stem cells than in non-tumor stem cells. Therefore, 18 genes such as RPS4X can be used for distinguishing lung adenocarcinoma tumor stem cells from non-tumor stem cells.
While the invention has been described with respect to a preferred embodiment, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention. Those skilled in the art can make various changes, modifications and equivalent arrangements, which are equivalent to the embodiments of the present invention, without departing from the spirit and scope of the present invention, and which may be made by utilizing the techniques disclosed above; meanwhile, any changes, modifications and variations of the above-described embodiments, which are equivalent to those of the technical spirit of the present invention, are within the scope of the technical solution of the present invention.

Claims (5)

1. A genetic marker for identifying lung adenocarcinoma tumor stem cells, wherein the genetic marker comprises at least one of genes RPS4X, FTH1, CYBA, POMP, SLC25a5, RPL35A, BST2, SEC61G, HMGB1, COMMD6, CLIC1, COX6B1, NDUFB4, TPI1, COX8A, SAP18, HMGN1, and XIST.
2. The use of the genetic marker for identifying lung adenocarcinoma tumor stem cells as claimed in claim 1 in the preparation of a diagnostic kit for detecting lung adenocarcinoma tumor stem cells.
3. The use of the gene marker for identifying lung adenocarcinoma tumor stem cells according to claim 1 in the preparation of a diagnostic kit for lung adenocarcinoma prognosis.
4. The use of the gene marker for identifying lung adenocarcinoma tumor stem cells according to claim 1 in the preparation of a medicament for treating lung adenocarcinoma.
5. The use of the genetic marker of claim 1 for identifying lung adenocarcinoma tumor stem cells in non-diagnostic and non-therapeutic methods.
CN202111218705.7A 2021-10-20 2021-10-20 Gene marker for identifying lung adenocarcinoma tumor stem cells and application thereof Pending CN113755602A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111218705.7A CN113755602A (en) 2021-10-20 2021-10-20 Gene marker for identifying lung adenocarcinoma tumor stem cells and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111218705.7A CN113755602A (en) 2021-10-20 2021-10-20 Gene marker for identifying lung adenocarcinoma tumor stem cells and application thereof

Publications (1)

Publication Number Publication Date
CN113755602A true CN113755602A (en) 2021-12-07

Family

ID=78784186

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111218705.7A Pending CN113755602A (en) 2021-10-20 2021-10-20 Gene marker for identifying lung adenocarcinoma tumor stem cells and application thereof

Country Status (1)

Country Link
CN (1) CN113755602A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090062144A1 (en) * 2007-04-03 2009-03-05 Nancy Lan Guo Gene signature for prognosis and diagnosis of lung cancer
CN113151460A (en) * 2021-01-29 2021-07-23 复旦大学附属中山医院 Gene marker for identifying lung adenocarcinoma tumor cells and application thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090062144A1 (en) * 2007-04-03 2009-03-05 Nancy Lan Guo Gene signature for prognosis and diagnosis of lung cancer
CN113151460A (en) * 2021-01-29 2021-07-23 复旦大学附属中山医院 Gene marker for identifying lung adenocarcinoma tumor cells and application thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
张洪彬;张满娥;: "干细胞标志物Nanog基因检测在肺癌诊断中的临床意义", 中国实验诊断学, no. 12, pages 2155 - 2157 *

Similar Documents

Publication Publication Date Title
CN103299188A (en) Molecular diagnostic test for cancer
CN106834462A (en) One group of application of stomach oncogene
Seike et al. Proteomic signature of human cancer cells
CA2724312A1 (en) Biomarkers for the identification, monitoring, and treatment of head and neck cancer
WO2020048518A1 (en) Group of genes for molecular typing of medulloblastoma and use thereof
CN113151460B (en) Gene marker for identifying lung adenocarcinoma tumor cells and application thereof
CN110257382A (en) The aptamer and its screening technique and purposes of identification intestinal cancer serum markers
CN105067822A (en) Marker for diagnosing esophagus cancer
CN115032397B (en) Gastric cancer prognosis molecular marker
CN115992229B (en) lncRNA marker and model for pancreatic cancer prognosis risk assessment and application thereof
CN115678994A (en) Biomarker combination, reagent containing biomarker combination and application of biomarker combination
CN106164676A (en) SRM for PD L1 measures
CN107273717A (en) A kind of detection model of Sera of Lung Cancer gene and its construction method and application
CN105624166B (en) A kind of aptamer for detecting Human Bladder Transitional Cell Carcinoma cell and its application in detection preparation is prepared
Langbein et al. Protein profiling of bladder cancer using the 2D-PAGE and SELDI-TOF-MS technique
CN109735619B (en) Molecular marker related to non-small cell lung cancer prognosis and application thereof
Xu et al. MALDI‐MS derived prognostic protein markers for resected non‐small cell lung cancer
CN113755602A (en) Gene marker for identifying lung adenocarcinoma tumor stem cells and application thereof
CN107312778B (en) A kind of cancer diagnosing kit and treatment pharmaceutical composition
CN116179704A (en) Application of TRIM21 as nasopharyngeal carcinoma radiotherapy efficacy prediction marker
CN106093241A (en) Can be used for mark detecting laryngeal carcinoma and application thereof
CN112485429A (en) Method for researching drug resistance of non-small cell lung cancer to pemetrexed
US20190360028A1 (en) Method of distinguishing lung squamous cell carcinoma from head and neck squamous cell carcinoma
CN116240283B (en) Application of OMA1 in reversing acute lymphoblastic leukemia drug resistance
CN108823308A (en) Detect application and the kit of circMAN1A2 and LOC284454 reagent

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20211207